The FDA boxed warning on Wegovy, Ozempic, Mounjaro, and Zepbound — about thyroid C-cell tumors — comes specifically from rodent studies where rats given high-dose GLP-1 RA developed thyroid C-cell tumors. Whether this translates to humans is the actual question.
Multiple post-market surveillance studies in humans, including a 2024 JAMA analysis of >170,000 GLP-1 RA users, have not detected elevated medullary thyroid carcinoma incidence vs matched controls. The relative risk in the most-cited cohort (Bezin et al., 2023) appeared elevated but was confounded by surveillance bias (GLP-1 users get more screening).
What is actually contraindicated
- Personal history of medullary thyroid carcinoma
- Family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia type 2 (MEN-2) syndrome
For patients without these specific risk factors, current evidence does not support avoiding GLP-1 medications on thyroid cancer grounds alone. The rodent-data warning persists on labeling because regulatory caution outweighs ambiguous human evidence, not because the human signal has materialized.
Discuss your individual risk profile with your clinician before starting. We are not your clinician.